Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pedersen-Bjergaard

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancerJ Pedersen-Bjergaard, T C Sigsgaard, D Nielsen, et al.
The New England Journal of Medicine|April 21, 1988
Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphomaJ Pedersen-Bjergaard, J Ersbøll, V L Hansen, et al.
Leukemia|June 1, 1991
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, DenmarkO P Hansen, J Pedersen-Bjergaard, J Ellegaard, et al.
Leukemia|December 1, 1993
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen seriesJ Pedersen-Bjergaard, P Philip, S O Larsen, et al.
Leukemia|January 1, 1997
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AMLP de Nully Brown, T Hoffmann, O P Hansen, et al.
Blood|December 15, 1993
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase IIH J Super, N R McCabe, M J Thirman, et al.
European Journal of Haematology|September 30, 1998
BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatmentC H Geisler, M M Hansen, N S Andersen, et al.
Scandinavian Journal of Haematology|July 1, 1980
Radiotherapy versus radiotherapy plus chemotherapy in stages I and II Hodgkin's disease. A prospective, randomized study by the Danish National Hodgkin Study Group, LYGRAN I Nissen, A M Nordentoft, H Brincker, et al.
Cancer Research|March 15, 1996
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11M A Caligiuri, M P Strout, S A Schichman, et al.
Cancer|January 1, 1979
A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, O Glidewell, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancerJ Pedersen-Bjergaard, T C Sigsgaard, D Nielsen, et al.
The New England Journal of Medicine|April 21, 1988
Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphomaJ Pedersen-Bjergaard, J Ersbøll, V L Hansen, et al.
Leukemia|June 1, 1991
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, DenmarkO P Hansen, J Pedersen-Bjergaard, J Ellegaard, et al.
Leukemia|December 1, 1993
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen seriesJ Pedersen-Bjergaard, P Philip, S O Larsen, et al.
Leukemia|January 1, 1997
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AMLP de Nully Brown, T Hoffmann, O P Hansen, et al.
Blood|December 15, 1993
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase IIH J Super, N R McCabe, M J Thirman, et al.
European Journal of Haematology|September 30, 1998
BEAM+autologous stem cell transplantation in malignant lymphoma: 100 consecutive transplants in a single centre. Efficacy, toxicity and engraftment in relation to stem-cell source and previous treatmentC H Geisler, M M Hansen, N S Andersen, et al.
Scandinavian Journal of Haematology|July 1, 1980
Radiotherapy versus radiotherapy plus chemotherapy in stages I and II Hodgkin's disease. A prospective, randomized study by the Danish National Hodgkin Study Group, LYGRAN I Nissen, A M Nordentoft, H Brincker, et al.
Cancer Research|March 15, 1996
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11M A Caligiuri, M P Strout, S A Schichman, et al.
Cancer|January 1, 1979
A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group BN I Nissen, T F Pajak, O Glidewell, et al.
Pageof 10